Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL

Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.

Related Keywords

United Kingdom ,Andyc Rawstron , ,United Kingdom National Health Service ,International Workshop ,Hematological Malignancy Diagnostic Service ,Leeds Cancer Centre ,Kingdom National Health Service ,Lancet Oncology ,Ibrutinib ,Cll ,Chronic Lymphocytic Leukemia ,Iwcll ,